Patents Assigned to MedImmune, LLC
  • Patent number: 10011660
    Abstract: Provided are polypeptides comprising a variant IgG Fc domain, wherein the polypeptides exhibit reduced or ablated effector functions (e.g., ADCC and/or CDC) and increased stability and plasma half-life compared to a parent polypeptide. Also provided are compositions, methods of treatment, and methods to diminish Fc-induced effector function in a parent polypeptide.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: July 3, 2018
    Assignee: MedImmune, LLC
    Inventors: Ping Tsui, Martin Borrok, II, William Dall'Acqua
  • Patent number: 10006026
    Abstract: Disclosed herein is a method for producing a recombinant polypeptide in a mammalian cell culture in which the mammalian cells have a modified microRNA activity level. In one embodiment, a microRNA activity level is increased. In another embodiment, a microRNA activity level is decreased. In a more particular embodiment, the mammalian cells have a reduced miRNA-let-7a activity level.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 26, 2018
    Assignee: MedImmune, LLC
    Inventors: Katie Streicher, Jonathan Jacobs, Robert W. Georgantas, III, Lydia Greenlees, Koustubh Ranade, Michael Bowen
  • Patent number: 9957312
    Abstract: Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by ThI, ThI 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1?, TNF-?, TGF-beta, IFN-?, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: May 1, 2018
    Assignee: MedImmune, LLC
    Inventors: Solomon Langermann, Linda Liu, Joseph R. Podojil, Stephen D. Miller, Shannon Marshall
  • Publication number: 20180079813
    Abstract: Antibodies and humanized variants thereof and their antigen-binding fragments and other molecules that are capable of immunospecifically binding to the B7-H7 counter-receptor, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.
    Type: Application
    Filed: September 19, 2017
    Publication date: March 22, 2018
    Applicants: MEDIMMUNE, LLC, THE JOHNS HOPKINS UNIVERSITY
    Inventors: SOLOMON LANGERMANN, LINDA LIU, SHENG YAO, LIEPING CHEN
  • Patent number: 9920124
    Abstract: The present invention provides methods of preparing active immunoconjugates, including anti-CD22 immunoconjugates. Suitably, the methods include a fed-batch refolding process and/or column stripping process that result in an increase in yield of the immunoconjugate over other processes that do not utilize the methods.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: March 20, 2018
    Assignee: MedImmune, LLC
    Inventors: Alan Hunter, Thomas Linke, Timothy Pabst, Michaela Wendeler, Xiangyang Wang, Christopher Thompson, Guoling Xi, Andrew Fulton
  • Patent number: 9913894
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: March 13, 2018
    Assignee: MedImmune, LLC
    Inventors: Guillermo Tous, Mark Schenerman, Jose Casas-Finet, Ziping Wei, David Pfarr
  • Publication number: 20180066056
    Abstract: Antibodies and humanized variants thereof and their antigen-binding fragments and other molecules that are capable of immunospecifically binding to the B7-H7 counter-receptor, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.
    Type: Application
    Filed: September 19, 2017
    Publication date: March 8, 2018
    Applicants: MEDIMMUNE, LLC, THE JOHNS HOPKINS UNIVERSITY
    Inventors: SOLOMON LANGERMANN, LINDA LIU, SHENG YAO, LIEPING CHEN
  • Patent number: 9896505
    Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: February 20, 2018
    Assignee: MedImmune, LLC
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • Patent number: 9879067
    Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulation exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulation are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: January 30, 2018
    Assignee: MedImmune, LLC
    Inventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
  • Patent number: 9879070
    Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: January 30, 2018
    Assignee: MedImmune, LLC
    Inventors: Brett Sellman, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang
  • Publication number: 20180022807
    Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.
    Type: Application
    Filed: May 5, 2017
    Publication date: January 25, 2018
    Applicant: MEDIMMUNE, LLC
    Inventors: Srinath KASTURIRANGAN, CHANGSHOU GAO, GODFREY RAINEY, MICHELLE MORROW, CLAIRE LOUISE DOBSON, STACEY DRABIC, DARREN SCHOFIELD, GIANLUCA CARLESSO, KRISTEN POLLIZZI, YARIV MAZOR, MICHAEL OBERST, SCOTT A. HAMMOND, BRIAN LOBO, PRAKASH MANIKWAR, JONATHAN SEAMAN
  • Patent number: 9862762
    Abstract: This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: January 9, 2018
    Assignee: MEDIMMUNE, LLC
    Inventors: Partha Chowdhury, Reena Varkey, Meina Liang, Yen-Wah Lee, Katie Streicher, Koustubh Ranade, Ethan Grant, Lydia Greenlees, Yihong Yao, Melissa Parker
  • Patent number: 9845348
    Abstract: The present invention provides for methods of preventing and/or treating S. aureus-associated bacteremia and sepsis, and methods for preventing and/or treating S. aureus-associated pneumonia in immunocompromised patients using anti-S. aureus alpha-toxin (anti-AT) antibodies. Also provided are methods of reducing S. aureus bacterial load in the bloodstream or heart of a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof. Methods of reducing S. aureus bacterial agglutination and/or thromboembolic lesion formation in a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, are also provided. Also provided are methods of preventing or reducing the severity of S. aureus associated pneumonia in an immunocompromised mammalian subject.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: December 19, 2017
    Assignee: MedImmune, LLC
    Inventors: Brett Sellman, Christine Tkaczyk, Melissa Hamilton, Lei Hua
  • Patent number: 9790277
    Abstract: Antibodies and humanized variants thereof and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the B7-H7 counter-receptor, H7CR, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: October 17, 2017
    Assignees: The Johns Hopkins University, MedImmune, LLC
    Inventors: Solomon Langermann, Linda Liu, Sheng Yao, Lieping Chen
  • Patent number: 9738723
    Abstract: The disclosure provides humanized anti-OX40 antibodies. Also provided are methods of making such antibodies, and methods of use, e.g., treatment of cancer.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: August 22, 2017
    Assignee: MedImmune, LLC
    Inventors: Scott A. Hammond, Michael Oberst, Qun Du, Melissa Damschroder
  • Patent number: 9718870
    Abstract: The disclosure provides OX40L huIgG4 fusion polypeptide subunits comprising a human IgG4 Fc domain, a trimerization domain, and the receptor binding domain of Ox40 ligand, where the fusion polypeptide subunits can self-assemble into hexameric proteins. Also provided are methods of making fusion polypeptide subunits and hexameric proteins, and methods of use, e.g., treatment of cancer.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: August 1, 2017
    Assignee: MedImmune, LLC
    Inventors: Melissa Damschroder, Michael Oberst, Scott Hammond, Hui Feng
  • Publication number: 20170204362
    Abstract: This application provides improved cell culture media and cell culture methods comprising N-acetylcysteine. These improved cell culture media and cell culture methods increase cell viability, cellular growth rate and/or reduce cell doubling time of cholesterol auxotrophic cells, myeloma cells, and hybridoma cells.
    Type: Application
    Filed: June 17, 2015
    Publication date: July 20, 2017
    Applicant: Medimmune, LLC
    Inventors: Brena Holman, Jeong Lee
  • Patent number: 9676854
    Abstract: The present invention relates to antibodies (including anti-B7-H4 antibodies) and their antigen-binding fragments and to other molecules (including fusion proteins that bind to the cognate antigen/receptor, etc.) that are capable of immunospecifically binding to B7-H4 and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases. The invention particularly concerns the use of such molecules to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor associated macrophages (“TAMs”) so as to alter their activity and/or decrease TAM—mediated immune suppression.
    Type: Grant
    Filed: August 15, 2012
    Date of Patent: June 13, 2017
    Assignee: MedImmune, LLC
    Inventors: Linda Liu, Shannon Marshall, Solomon Langermann
  • Publication number: 20170121771
    Abstract: The present invention encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.
    Type: Application
    Filed: October 11, 2016
    Publication date: May 4, 2017
    Applicant: MEDIMMUNE, LLC
    Inventors: YIHONG YAO, BAHIJA JALLAL, RICARDO CIBOTTI, ANTHONY COYLE, PETER KIENER
  • Patent number: D821572
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: June 26, 2018
    Assignee: MedImmune, LLC
    Inventors: Corbin Zean Clawson, Roger Wongjung Liu, Janardhanan Anand Subramony